Search

Your search keyword '"Fløisand, Yngvar"' showing total 238 results

Search Constraints

Start Over You searched for: Author "Fløisand, Yngvar" Remove constraint Author: "Fløisand, Yngvar"
238 results on '"Fløisand, Yngvar"'

Search Results

4. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia

5. Early response evaluation by single cell signaling profiling in acute myeloid leukemia

6. Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia

9. A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT

12. DNA glycosylase Neil3 regulates vascular smooth muscle cell biology during atherosclerosis development

13. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

14. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

15. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation

17. Allogeneic stem cell transplantation in adults 2015–21

18. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

20. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

22. Identifying predictors of survival in patients with leukemia using single-cell mass cytometry and machine learning

23. Decidual stromal cells for the treatment of severe COVID-19 ARDS.

24. Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

27. Early response evaluation by single cell signaling profiling in acute myeloid leukemia

28. A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT

30. Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG

31. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014 : improving performance status is a major contributing factor

32. A cell competition–based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

34. A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

36. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor

37. Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

38. Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

42. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells

43. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review

44. Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

45. A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

47. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome

Catalog

Books, media, physical & digital resources